Sentiment-Signal
13,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Unternehmen & Branche
| Name | Biohaven Ltd. |
|---|---|
| Ticker | BHVN |
| CIK | 0001935979 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 980,8 Mio. USD |
| Beta | 3,62 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -738,822,000 | -6.86 | 451,447,000 | 52,072,000 | |
| 2025-09-30 | 10-Q | -173,443,000 | -1.64 | 409,123,000 | -17,160,000 | |
| 2025-06-30 | 10-Q | -198,147,000 | -1.94 | 550,415,000 | 134,587,000 | |
| 2025-03-31 | 10-Q | -221,677,000 | -2.17 | 458,946,000 | 259,495,000 | |
| 2024-12-31 | 10-K | -846,422,000 | -9.28 | 615,107,000 | 423,436,000 | |
| 2024-09-30 | 10-Q | -160,304,000 | -1.70 | 510,523,000 | 316,006,000 | |
| 2024-06-30 | 10-Q | -319,771,000 | -3.64 | 582,641,000 | 383,740,000 | |
| 2024-03-31 | 10-Q | -179,504,000 | -2.20 | 418,532,000 | 301,447,000 | |
| 2023-12-31 | 10-K | -408,168,000 | -5.73 | 513,212,000 | 427,975,000 | |
| 2023-09-30 | 10-Q | -102,574,000 | -1.50 | 382,736,000 | 290,006,000 | |
| 2023-06-30 | 10-Q | -90,346,000 | -1.32 | 506,736,000 | 387,255,000 | |
| 2023-03-31 | 10-Q | -70,492,000 | -1.03 | 618,521,000 | 472,258,000 | |
| 2022-12-31 | 10-K | -570,279,000 | -12.75 | 661,783,000 | 538,771,000 | |
| 2022-09-30 | 10-Q | -68,853,000 | -1.75 | 135,646,000 | 100,216,000 | |
| 2022-06-30 | 10-Q | -203,287,000 | -5.16 | 24,998,000 | ||
| 2022-03-31 | 10-Q | -97,032,000 | -2.46 | 46,099,000 | ||
| 2021-12-31 | 10-K | -213,796,000 | -5.43 | 142,061,000 | 34,691,000 | |
| 2021-09-30 | 10-Q | -54,365,000 | -1.38 | 321,510,000 | ||
| 2021-06-30 | 10-Q | -45,423,000 | 42,132,000 | |||
| 2021-03-31 | 10-Q | -62,122,000 | 47,873,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | Clark George C. | Officer, VP, Chief Accounting Officer | Open Market Purchase | 17,000 | 8.52 | 144,770.30 | +1,9% | |
| 2025-11-13 | CHILDS JOHN W | Director | Open Market Purchase | 3,333,333 | 7.50 | 24,999,997.50 | +326,3% | |
| 2025-11-13 | Coric Vlad | Director, Officer, Chief Executive Officer | Open Market Purchase | 333,333 | 7.50 | 2,499,997.50 | +32,6% | |
| 2025-11-13 | Bailey Gregory | Director | Open Market Purchase | 400,000 | 7.50 | 3,000,000.00 | +39,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.